# The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate

> **NCT00427219** · PHASE2 · COMPLETED · sponsor: **Spectrum Pharmaceuticals, Inc** · enrollment: 74 (actual)

## Conditions studied

- Benign Prostatic Hypertrophy

## Interventions

- **DRUG:** Ozarelix
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00427219
- **Lead sponsor:** Spectrum Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01-23
- **Primary completion:** 2008-02-27
- **Final completion:** 2008-02-27
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2021-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00427219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00427219, "The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00427219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*